Interview 11 Sep 2017 Meet the CEO of Europe’s Largest & Most Fiercely Independent Biotech …example, a bispecific antibody, we can do this in-house. We’ve been able to create two completely new next-generation antibody technology platforms, DuoBody and HexaBody for bispecific and immune effector function… September 11, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2023 Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered …to $2.2 billion in milestone payments in exchange for Bristol Myers Squibb’s access to its antibody oligonucleotide conjugates (AOC) platform technology. The platform combines the technology of monoclonal antibodies and… December 1, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Sep 2018 10 Biotech Companies in Berlin You Should Know …clinical trials for ovarian and squamous cell carcinoma. The company recently signed a licensing agreement with Daiichi Sankyo to combine this antibody with the Japanese pharma’s antibody-drug conjugate technology. Noxxon… September 10, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Positive results of cancer treatment to be presented at Boston conference …in Boston. Alderaan Biotechnology is a preclinical biotech company that focuses on monoclonal antibody development. It will be making announcements about the most recent development of its new antibody candidate,… November 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 AbbVie acquires LifeArc portfolio company DJS Antibodies AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled… October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2019 MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II Development of MorphoSys, Galapagos, and Novartis’ first-in-class antibody drug has been discontinued during a phase II trial after an interim analysis suggested it wouldn’t meet its main endpoint of reducing… October 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II …antibody’s efficacy and safety. AC Immune’s anti-Tau monoclonal antibody is based on the company’s SupraAntigen technology. They are generated by injecting the SupraAntigen constructs into mice and selecting antibodies that… November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Mar 2025 AbbVie and Genmab: Can a legal battle break a billion-dollar bond? …technology related to antibody-drug conjugates (ADCs). Genmab has rejected the claims and said it will defend itself, insisting the dispute will not impact its ongoing collaborations with AbbVie. But it’s… March 25, 2025 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Sep 2023 Five biotech companies taking Los Angeles by storm …high potency and a small molecular size – about one-tenth the size of a traditional monoclonal antibody – it can reach high drug exposure levels through a single, subcutaneous injection…. September 19, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2022 Fast Stroke Treatments in the Works with TargED’s €39M Series A …Microlyse is a fusion protein drug combining an antibody fragment with a fragment of a clot-busting enzyme. The antibody part of the drug seeks out a protein target found in… February 22, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Researchers identify possible target for type of sporadic ALS …cells. When a synthetic antibody designed specifically to recognize HERV-K ENV was added as well to those neurons, the toxic effects were reduced. These findings together suggest that the improper… August 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2020 Adrenomed’s Antibody Drug Scores Hit in Phase II Septic Shock Trial German biotech Adrenomed reports that its first-in-class antibody drug adrecizumab was well-tolerated by septic shock patients and met its primary goal in a phase II trial. The company says it… February 24, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email